Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials
Objective: To review the comparative effectiveness of osteoporosis treatments, including the bone anabolic agents, abaloparatide and romosozumab, on reducing the risk of fractures in postmenopausal women, and to characterise the effect of antiosteoporosis drug treatments on the risk of fractures acc...
Principais autores: | Händel, MN, Cardoso, I, von Bülow, C, Rohde, JF, Ussing, A, Nielsen, SM, Christensen, R, Body, J, Brandi, ML, Diez-Perez, A, Hadji, P, Javaid, MK, Lems, WF, Nogues, X, Roux, C, Minisola, S, Kurth, A, Thomas, T, Prieto-Alhambra, D, Ferrari, SL, Langdahl, B, Abrahamsen, B |
---|---|
Formato: | Journal article |
Idioma: | English |
Publicado em: |
British Medical Journal Publishing Group
2023
|
Registros relacionados
-
Comparative risk of acute myocardial infarction for anti-osteoporosis drugs in primary care: a meta-analysis of propensity-matched cohort findings from the UK Clinical Practice Research Database and the Catalan SIDIAP Database
por: Khalid, S, et al.
Publicado em: (2022) -
Comment on Tadrous et al.: comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis.
por: Pazianas, M, et al.
Publicado em: (2014) -
Living network meta-analysis compared with pairwise meta-analysis in comparative effectiveness research: empirical study.
por: Nikolakopoulou, A, et al.
Publicado em: (2018) -
Large scale prospective meta-analysis of BMD and fracture in relation to COLIA1 Sp1 polymorphism: The GENOMOS study.
por: Ralston, S, et al.
Publicado em: (2005) -
MetaComp: comprehensive analysis software for comparative meta-omics including comparative metagenomics
por: Peng Zhai, et al.
Publicado em: (2017-10-01)